Glutamate Dysfunction in People with Prodromal Symptoms of Psychosis: Relationship to Gray Matter Volume

[1]  E. Bullmore,et al.  Meta-Analysis of Gray Matter Anomalies in Schizophrenia: Application of Anatomic Likelihood Estimation and Network Analysis , 2008, Biological Psychiatry.

[2]  C. Gaser,et al.  Structural brain alterations in subjects at high-risk of psychosis: A voxel-based morphometric study , 2008, Schizophrenia Research.

[3]  D. Javitt,et al.  Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia , 2008, Trends in Neurosciences.

[4]  Hilleke E. Hulshoff Pol,et al.  Progressive Brain Volume Loss in Schizophrenia Over the Course of the Illness: Evidence of Maturational Abnormalities in Early Adulthood , 2008, Biological Psychiatry.

[5]  Ravi S. Menon,et al.  Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia , 2007, British Journal of Psychiatry.

[6]  James M. Stone,et al.  Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review , 2007, Journal of psychopharmacology.

[7]  Philip K. McGuire,et al.  Regional Gray Matter Volume Abnormalities in the At Risk Mental State , 2007, Biological Psychiatry.

[8]  L. Rowland,et al.  Regarding “Increased Prefrontal and Hippocampal Glutamate Concentration in Schizophrenia: Evidence from a Magnetic Resonance Spectroscopy Study” , 2007, Biological Psychiatry.

[9]  Edgar Erdfelder,et al.  G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences , 2007, Behavior research methods.

[10]  Tyrone D. Cannon,et al.  ’ s Introduction : The Empirical Status of the Ultra High-Risk ( Prodromal ) Research Paradigm , 2007 .

[11]  R. S. Kahn,et al.  Brain volume changes in the first year of illness and 5-year outcome of schizophrenia , 2006, British Journal of Psychiatry.

[12]  J. Lieberman,et al.  Brain volume in first-episode schizophrenia , 2006, British Journal of Psychiatry.

[13]  J. Bustillo,et al.  What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update , 2006, Current opinion in psychiatry.

[14]  J. Krystal,et al.  First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients , 2006, Molecular Psychiatry.

[15]  B. Barbiroli,et al.  Assessment of glutamate and glutamine contribution to in vivo N‐acetylaspartate quantification in human brain by 1H‐magnetic resonance spectroscopy , 2005, Magnetic resonance in medicine.

[16]  Martin Büchert,et al.  Increased Prefrontal and Hippocampal Glutamate Concentration in Schizophrenia: Evidence from a Magnetic Resonance Spectroscopy Study , 2005, Biological Psychiatry.

[17]  P. Sundgren,et al.  Magnetic resonance spectroscopy. , 2005, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[18]  S. Strakowski,et al.  Changes in Gray Matter Volume in Patients with Bipolar Disorder , 2005, Biological Psychiatry.

[19]  J. Lauriello,et al.  Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. , 2005, The American journal of psychiatry.

[20]  P. Williamson,et al.  Duration of untreated psychosis vs. N-acetylaspartate and choline in first episode schizophrenia: a 1H magnetic resonance spectroscopy study at 4.0 Tesla , 2004, Psychiatry Research: Neuroimaging.

[21]  Mark Weiser,et al.  Higher Rates of Cigarette Smoking in Male Adolescents Before the Onset of Schizophrenia: A Historical-Prospective Cohort Study , 2004 .

[22]  C. Hanstock,et al.  3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. , 2004, The American journal of psychiatry.

[23]  Paul J. Harrison.  The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications , 2004, Psychopharmacology.

[24]  Ravi S. Menon,et al.  Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. , 2003, The American journal of psychiatry.

[25]  Fahmeed Hyder,et al.  In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. , 2003, Annual review of physiology.

[26]  D. Goff,et al.  Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia , 2003, Annals of the New York Academy of Sciences.

[27]  D. Lorrain,et al.  Effects of ketamine and n-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268 , 2003, Neuroscience.

[28]  Hok Pan Yuen,et al.  Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group , 2003, Schizophrenia Research.

[29]  John Suckling,et al.  For personal use. Only reproduce with permission from The Lancet Publishing Group. Effect of sunlight and season on serotonin turnover in the brain , 2002 .

[30]  Ravi S. Menon,et al.  Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. , 2002, The American journal of psychiatry.

[31]  J. Deakin,et al.  Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses , 2001, Neuroreport.

[32]  J. Coyle,et al.  The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. , 2001, The American journal of psychiatry.

[33]  Myriam Bernaudin,et al.  Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? , 2001, Trends in Neurosciences.

[34]  S. Deutsch,et al.  A Revised Excitotoxic Hypothesis of Schizophrenia: Therapeutic Implications , 2001, Clinical neuropharmacology.

[35]  A. Yung,et al.  Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. , 2000, The Australian and New Zealand journal of psychiatry.

[36]  D J Healy,et al.  Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. , 1998, The American journal of psychiatry.

[37]  Bita Moghaddam,et al.  Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.

[38]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[39]  S. Provencher.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[40]  J. Ehrhardt,et al.  T1 and T2 relaxation times in schizophrenia as measured with magnetic resonance imaging , 1991, Schizophrenia Research.

[41]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[42]  M. Hamilton.  The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.

[43]  John Suckling,et al.  Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain , 1999, IEEE Transactions on Medical Imaging.

[44]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.